Mankind Pharma acquires Bharat Serums from Advent International for ₹13,630 crore.
Learn More
Company
Go Back Menu
About Mankind
Go Back Menu
Overview
Milestones
Management
Products
Partner With Us
Awards & Recognition
Our Initiatives
Quality
Manufacturing
About BSV
R&D & Innovation
Go Back Menu
Overview
Active Pharmaceutical Ingredients (API)
Formulation R&D
New Drug Discovery Research (NDDR)
Biotechnology
Analytical R&D
Intellectual Property Rights
Safety & Sustainability
Go Back Menu
Environment Health & Safety
Kind Care
International
Go Back Menu
North America
Emerging Markets
Investor Center
Go Back Menu
Investor Hub
Board Of Directors
Disclosures Under Regulation 46
Financials
Investor Presentations
Annual Reports
Intimation To Stock Exchange
Shareholder Information
Corporate Governance
Company Contact
Postal Ballot
Qualified Institutional Placement - PPD
Qualified Institutional Placement - PD
Careers
Go Back Menu
Life At Mankind
Current Openings
Blog
Media
Contact Us
Company
About Mankind
Overview
Milestones
Management
Products
Partner With Us
Awards & Recognition
Our Initiatives
Quality
Manufacturing
About BSV
We are driven by three core values of quality, affordability and accessibility.
R&D & Innovation
Overview
Active Pharmaceutical Ingredients (API)
Formulation R&D
New Drug Discovery Research (NDDR)
Biotechnology
Analytical R&D
Intellectual Property Rights
With 6 cutting-edge R&D facilities, we pioneer breakthroughs like Dydrogesterone in pharmaceutical excellence.
Safety & Sustainability
Environment Health & Safety
Kind Care
We have adopted policies aimed at complying with legislative requirements and ensuring the safety of our employees and the personnel working at our facilities or under our management.
International
North America
Emerging Markets
Committed towards a healthier and happier world, we strive to provide accessible and affordable healthcare to all sections of the society.
Investor Center
Investor Hub
Board Of Directors
Disclosures Under Regulation 46
Financials
Investor Presentations
Annual Reports
Intimation To Stock Exchange
Shareholder Information
Corporate Governance
Company Contact
Postal Ballot
Qualified Institutional Placement - PPD
Qualified Institutional Placement - PD
Mankind Pharma Ltd
NSE: MANKIND
-
-
Careers
Life At Mankind
Current Openings
Mankind Pharma is not just a workplace; it's a frontier of innovation. Join us in leveraging science to shape a healthier Bharat.
Shop
Blog
Media
Contact Us
Discover more of Mankind
Close
OUR KEY MILESTONES
Through the timeline, growth reveals its evolution.
2024
2023
2022
2021
2018
2015
2012
2007-10
2004
1995
Acquired 100% stake in BSV Limited
Entered into in-licensing agreements with Astra Zeneca - Symbicort, Novartis - Crenzlo (Inclisiran), Takeda – Vonalong and Vonatime (Vonoprazan)
Successfully listed on NSE and BSE
Launch of International Quality API- Products
Commercialised India’s First fully integrated facility for Dydrogesterone at Udaipur
Acquired brands of Panacea Biotec Pharma Limited enabling entry into transplant and oncology
Acquired ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories
Launched dedicated specialty divisions for cardiovascular, respiratory, Central Nervous System and Diabetes segments
Paonta Sahib facility inspected by the USFDA for the first time
First Indian Company to launch “Dydrogesterone ”
Incorporated our subsidiaries in the US and Singapore
Set up first R&D center at IMT Manesar, Haryana
Entered consumer healthcare by launching Manforce and Prega News brands
Entered chronic pharmaceutical Segment
Commenced operation in 1995 (Founded in 1991)